Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 28, 2014; 20(12): 3231-3244
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3231
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3231
Biomarkers in inflammatory bowel diseases: Current status and proteomics identification strategies
Tue Bennike, Svend Birkelund, Allan Stensballe, Department of Health Science and Technology, Aalborg University, 9220 Aalborg, Denmark
Vibeke Andersen, Institute of Regional Health Research, University of Southern Denmark, 5000 Odense C, Denmark
Vibeke Andersen, Organ Center, Hospital of Southern Jutland, 6200 Aabenraa, Denmark
Author contributions: Bennike T wrote and revised the article; Birkelund S, Stensballe A and Andersen V helped critical review and provided suggestions; Bennike T finalized the revision.
Correspondence to: Vibeke Andersen, MD, PhD, Organ Center, Hospital of Southern Jutland, Kresten Philipsens Vej 15, 6200 Aabenraa, Denmark. vibeke.andersen1@rsyd.dk
Telephone: +45-2980-1078 Fax: +45-8883-4488
Received: September 27, 2013
Revised: January 13, 2014
Accepted: February 20, 2014
Published online: March 28, 2014
Processing time: 180 Days and 16.2 Hours
Revised: January 13, 2014
Accepted: February 20, 2014
Published online: March 28, 2014
Processing time: 180 Days and 16.2 Hours
Core Tip
Core tip: Establishing the correct diagnose of Crohn’s disease and ulcerative colitis (UC) patients remains troublesome, and correct and early medication is critical. No reliable biomarkes have been implemented in clinical usage, to distinguish between Crohn’s disease patients and UC patients. Considering the protein complexity encountered in intestinal biopsy samples and the recent development within the field of quantitative proteomics, submitting the intestinal mucosa to a more thorough analysis has the potential to reveal new biomarkers.